21 August 2017 - Once daily Duzallo is the first FDA approved fixed-dose combination treatment that addresses both causes of hyperuricaemia in gout, over-production and under-excretion of serum uric acid, in a single pill.

Ironwood Pharmaceuticals today announced Duzallo was approved by the U.S. FDA as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone. 

Duzallo is not recommended for the treatment of asymptomatic hyperuricemia. Ironwood expects Duzallo to be commercially available early in the fourth quarter of 2017.

Read Ironwood Pharmaceuticals press release